Document:

EX-10.17

 Exhibit 10.17 

Durata Therapeutics, Inc. 

Director Compensation and Reimbursement Policy 

This Director Compensation and Reimbursement Policy of Durata Therapeutics, Inc. (the “Corporation”) provides for
compensation of each member of the Board of Directors (the “Board”) of the Corporation who is not an employee of the Corporation or any subsidiary of the Corporation (a “non-employee director”). This Director
Compensation and Reimbursement Policy also provides for reimbursement of expenses for all members of the Board. 
 Annual Cash Retainers 

Each non-employee director is entitled to receive an annual cash retainer of $40,000 for service as a director. Each non-employee director who
serves as Chairman of the Board also is entitled to receive an additional annual cash retainer of $15,000. Each non-employee director also is entitled to receive the following additional annual cash retainer for service as the chair or other member
of the Board committees set forth below. 
  

									
	 	  	Annual Retainer for Service on
Board Committees	 
	 	  	        Chair        	 	  	        Other        	 
	 Committee
	  				  			
	 Audit Committee
	  	$	15,000	  	  	$	7,500	  
	 Organization and Compensation Committee
	  	$	10,000	  	  	$	5,000	  
	 Nominating and Corporate Governance Committee
	  	$	5,000	  	  	$	2,500	  

 Annual cash retainers for service as a non-employee director and as the chair or other member of a Board committee shall be
payable in arrears in four equal quarterly installments on the last day of each quarter; provided that the amount of such payment shall be prorated for any portion of such quarter that the director was not serving on the Board or the applicable
committee. 
 Equity Compensation 

After the effective date of the Corporation’s 2012 Stock Incentive Plan, as it may be amended from time to time (the “Plan”),
the Corporation shall grant to each non-employee director, on the date of the annual meeting of stockholders of the Corporation, (i) a nonstatutory stock option (an “Annual Option”) to purchase such number of shares of Common Stock
having a value, as of such date, that is equal to $75,000, as determined using the Black-Scholes option pricing model, and (ii) to the non-employee director who is serving as Chairman of the Board at the time of the annual meeting, if any, an
Annual Option to purchase such number of shares of Common Stock having a value, as of such date, that is equal to $15,000, as determined using the Black-Scholes option pricing model. An Annual Option shall vest in full after a period of 12 months
and, in the event of a change in control of the Corporation, the option will accelerate in full. 
 Annual Options shall (i) have an
exercise price equal to the Fair Market Value (as defined in the Plan) of the Corporation’s Common Stock on the date of grant, (ii) expire on the earlier of 10 years from the date of grant or 24 months following cessation of service on the
Board and (iii) contain such other terms and conditions as the Board shall determine. 
 The obligation to grant Annual Options under
the Plan to a non-employee director shall, if so determined by the Board, be reduced to the extent the Corporation is otherwise obligated to grant, or the Board otherwise grants or has granted, options to such non-employee director. 

Reimbursement of Expenses 
 The
Corporation shall reimburse each member of the Board for reasonable travel and other out-of-pocket expenses incurred in connection with attending meetings of the Board and its committees.EX-10.19

 Exhibit 10.19 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

FIRST AMENDMENT TO SUPPLY AGREEMENT 
 THIS
AMENDMENT is entered into this 29th day of August, 2013, by and between Gnosis Bioresearch srl, a subsidiary fully owned company by GNOSIS SPA organized under the laws of Italy whose head
office is located at Via Pomarico, 75010 Pisticci Scalo (MT), Italy, which is registered in the Commercial Register of Matera under No. 01023770777 (“Gnosis”), and Durata Therapeutics, Inc., a company organized under the
laws of the State of Delaware with offices at 200 S. Wacker Drive, Suite 2550, Chicago, IL 60606 USA (“Durata”) (collectively the “Parties”). 

WHEREAS, on June 12, 2012, the Parties executed a Supply Agreement (hereinafter “the Agreement”) concerning the manufacture and supply by
Gnosis of certain products for and to Durata; and 
 WHEREAS, pursuant to Section 15.4 of the Agreement, the Parties desire to memorialize certain
amendments to the Agreement which will form the First Amended Agreement. 
 NOW, THEREFORE, the Parties mutually agree to amend the Agreement as follows:

  

	 	1.	Article 1 is amended to include the following: “‘Facility Acceptance’ means that Durata is allowed by laws and regulations to commercially sell product manufactured at the Facility as evidenced by
either: (a) NDA for the Product is approved without FDA inspection of The Facility or (b) based on inspection performed by FDA, the Facility has been classified as “acceptable.” Acceptance is deemed achieved if following FDA
inspection of the facility, the FDA does not issue Form 483 or if the FDA issues form 483, such form does not include any critical or major observations that would render the FDA unable to approve the Facility. 

 

	 	2.	Article 1, definition of “Legal Requirements” is amended to include the following: “Notwithstanding anything to the contrary contained in this definition, “Legal Requirements”
specifically excludes Facility Acceptance as a requirement for the first [**] kg of Product manufactured by Gnosis and provided to Durata under this Agreement, subject to Section 5 below. 

 

	 	3.	Section 3.3(a) is amended to read: “Promptly after Effective Date the Parties shall enter into good faith discussions and use their respective good faith reasonable efforts to enter into a technical and
quality agreement (the “Quality Agreement”) no later than the [**] days after finalization of this Amendment following the most recent guidance of FDA: “Contract Manufacturing Arrangements for Drugs; Quality Agreements, “
and based on the terms set out in Exhibit 3.3(a) pursuant to which, among other things, Gnosis will conduct all quality control and release testing for the Product. 

 

	 	4.	The first sentence of Section 4.5(d) is amended to read: “In order to avoid a Supply Failure, at Durata’s written request, Gnosis agrees to have manufactured at Durata’s expense, and stored on-site
at the Facility, at least [**] Kilograms worth of safety stock (the “Safety Stock”) From [**] through end of the Term (or such other period of time as specified by Durata).” 

  
 Page 1 of 4 

	 	5.	Section 6.1 is amended by adding the following: Durata acknowledges that the first [**] kg of Product will be manufactured in [**] and maybe manufactured prior to Facility Acceptance. Durata agrees that Gnosis will
invoice Durata for the first [**] kg of Product, manufactured by Gnosis and provided to Durata under this agreement in the [**] and subject to the remainder of this section, Durata shall pay this invoice no later than [**]. Notwithstanding the
foregoing, if the Facility does not achieve Facility Acceptance by [**], Gnosis will refund to Durata this payment in full by [**] and Durata will have no further obligation to pay for any other Product produced at the Facility prior to [**].
Assuming Facility Acceptance, Gnosis will invoice Durata the remaining [**] kg at the later of conclusion of production (including passing all specifications) or at the time of Facility Acceptance, 

 

	 	6.	Section 6.2 is amended to include the following: Except as stated in Section 5 above,” Durata shall have no obligation to pay Gnosis any amounts for Product manufactured and supplied by Gnosis to Durata
hereunder (i) until Gnosis receives Facility Acceptance from the FDA; and (ii) to the extent that Durata would be restricted from making such Product commercially available due to restrictions imposed by a Regulatory Authority if such
restrictions arise from a failure of Gnosis to have Facility Acceptance to manufacture the Product at the time such Product was manufactured.” 

  

	 	7.	Section 10.1 is amended to read: “Term. This Agreement shall come into effect upon signature of this Agreement and shall continue, unless otherwise terminated pursuant to Section 10.2 or by
mutual agreement between the Parties until the fifth (5) anniversary of the Effective Date (the “Initial Term”). Thereafter, this Agreement shall automatically extend for additional terms of two (2) years (each, a
“Renewal Term” and the Renewal Term(s) together with the Initial Term, the “Term”) unless either Party provides the other Party written notice of its intent not to renew this Agreement at least twelve
(12) months prior to the end of the then applicable.” 

  

	 	8.	EXHIBIT 4.1 is replaced by “AMENDED EXHIBIT 4.1” (attached). 

 The complete First Amended Supply
Agreement and exhibits thereto, incorporating the foregoing amendments, are attached hereto. 

  
 Page 2 of 4 

 IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby as of the date of the date first
indicated above, have each executed this Amendment to the Agreement. 
  

					
	Durata Therapeutics, Inc.	 		 	Gnosis S.p.A.
			
	 /s/ Corey Fishman
	 		 	 /s/ Renzo Berna

	Signature	 		 	Signature
			
	 Corey Fishman
	 		 	 Renzo Berna

	Printed Name	 		 	Printed Name
			
	 COO/CFO
	 		 	 CEO

	Title	 		 	Title
			
	 August 29, 2013
	 		 	 29/8/13

	Date	 		 	Date

  
 Page 3 of 4 

 AMENDED EXHIBIT 4.1 

MINIMUM ANNUAL BINDING VOLUMES AND SUPPLY PRICES 

According to volumes indicated below, supply prices of Dalbavancin are: 
  

			
	Year 1 - 2014:	 	at least [**] kg at Euro [**] / kg.
		
		 	The initial [**] kg for 2014 will be produced in [**] and will be invoiced according to Section 5 above. Any amount over the initial [**] kg for 2014 will be invoiced upon definition of the total weights produced.
		
	Year 2 - 2015:	 	at least [**] kg at Euro [**] / kg.
		
		 	The initial [**] kg for 2015 will be produced in the [**] and will be invoiced in the [**]. Any amount over the initial [**] kg for 2015 will be invoiced upon definition of the total weights produced.
		
	Safety Stock	 	[**] kg Safety stock produced in [**] and invoiced in the [**], with payment due no later than [**].
		
	Year 3 - 2016:	 	at least [**] kg at Euro [**] / kg.
		
		 	The initial [**] kg for 2016 will be produced in the [**] and will be invoiced in the [**]. Any amount over the initial [**] kg for 2016 will be invoiced upon definition of the total weights produced.
		
	Years 4 - [**]:	 	Quantities and pricing to be defined no later than [**].

 Gnosis is the Main Supplier for the first [**] years of Product supply [**]. Main Supplier for the remaining years [**] will
be reconfirmed by [**]. 
  

	*	For Product manufactured in excess of the forgoing minimums in any given year, a reduced price will apply as follows: 

  

					
	 From Yearly Minimum (above) to [**] Kg
	  	 	–[**]% off	  
		
	 From [**] kg to [**] Kg
	  	 	–[**]% off	  
		
	 Above [**] Kg
	  	 	–[**]% off	  

 It is understood that Durata will pay Gnosis the full price for the first [**] years of minimum binding and safety stock
manufactured, notwithstanding any of the following: (i) the NDA for Product has not been approved by the FDA for reasons not imputable to Gnosis or (ii) submission of the NDA for Product has been withdrawn for any reason not imputable to
Gnosis activities, or (iii) the postponement or suspension of the launch of the Product on the market not imputable to the materials produced by Gnosis. 

  
 Page 4 of 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]